Navigation Links
HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs

successful treatment of HIV viral infection and control of AIDS. But hopefully our findings will save lives by alerting the physician to yet another side effect associated with this class of drug."

Dr. Ackerman is director of Mayo Clinic's Long QT Syndrome Clinic and Sudden Death Genomics Laboratory that specializes in various diseases and conditions that make a person vulnerable to sudden death by a ventricular arrhythmia.

There are several specific actions physicians can take to use this new information wisely, Drs. Ackerman and Badley say. The first is to screen by electrocardiogram for heart effects in vulnerable patients. The second is to be alert for multiple drug therapy situations, because certain drug-drug combinations could trigger the adverse heart side effects.

Background of the Discovery

Dr. Badley's research group earlier discovered that protease inhibitors affect "pore function" of "channels" in a specific cell type they were studying. Pore function in channels permits the exchange of biochemical signals within and between cells. After hearing of a case of heart rhythm disturbances in a patient taking protease inhibitors, the researchers looked for evidence of other patients with similar experiences. To do this, they used the U.S. Food and Drug Administration's voluntary drug side-effect database, the Adverse Event Reporting System. They identified 24 cases of heart rhythm disturbances -- all of which were associated with protease inhibitors.

They investigated the hypothesis that the widely-used protease inhibitors may, in fact, be linked to the development of heart rhythm problems through the mechanism of blocking a channel. Ultimately researchers from the University of Wisconsin led by Craig January, M.D., Ph.D., discovered that protease inhibitors do block these key channels.

"Our findings suggest that as a class, protease inhibitors may predispose individuals to QT interval problems or torsade de poi
'"/>

Source:Mayo Clinic


Page: 1 2 3

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
3. Implanted Devices Detect High-Risk Heart Failure Patients
4. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
5. Gene Signatures Predict Interferon Response For Multiple Sclerosis Patients
6. Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer
7. Single-donor Islet Transplantation Procedure Shows Promise For Patients With Type 1 Diabetes
8. IMF Launches World’s First DNA Database for Myeloma Patients
9. Patients now surviving once-fatal immune disease
10. Patients and their doctors have different perceptions about HIV and its treatment
11. Patients to benefit from novel technology revolutionizing high-speed molecular imaging
Post Your Comments:
(Date:7/27/2014)... study has revealed that nicotine and cotinine, a metabolite ... a certain carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone ... leaves and ultimately ends up in the tobacco smoke. ... liver, where it is activated by a variety of ... has revealed that nicotine can partially interfere with the ...
(Date:7/27/2014)... the southern Western Ghats, a mountain range along the west ... that any mayfly belonging to the genus Labiobaetis ... called Labiobaetis soldani , "is named in honor of ... of the Ephemeroptera of Palaearctic and Oriental realms," according to ... in the Journal of Insect Science . , The ...
(Date:7/27/2014)... at Barts Cancer Institute have found that targeting a ... more effective, according to research published in Nature ... part of Queen Mary University of London, have found ... the body to repair itself after chemotherapy or radiotherapy, ... researchers removed FAK from blood vessels that grew in ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2New drug target can break down cancer's barrier against treatment 2
... antibacterial medicine that kills the superbug MRSA is being ... Trust. The Seeding Drug Discovery initiative is aimed at ... unmet need. , Prolysis, an R&D company based ... Drug Discovery awards for its new antibacterial compounds aimed ...
... discovery in stem cell research may mean big things for ... a research team at the University of Kentucky published their ... , The researchers genetically mapped a stem cell gene and ... the investigation all the way through to the identification of ...
... as SORL1 may be a factor in the development of ... discovered. The genetic clue, which could lead to a better ... Genetics online, Jan. 14, 2007, and was supported in part ... researchers suggest that faulty versions of the SORL1 gene contribute ...
Cached Biology News:New antibacterials being developed to tackle MRSA superbug 2Researchers first to map gene that regulates adult stem cell growth 2Scientists find new genetic clue to cause of Alzheimer's disease 2
(Date:7/28/2014)... --  Propeller Health , the FDA-cleared digital health solution ... Brad Towle as Senior Vice President, Business and ... company,s sales growth, customer acquisition and program expansion. ... past role in the development of accountable care organizations, ... time in the industry," said David Van Sickle ...
(Date:7/28/2014)... 28, 2014 It’s a hard truth: Nearly ... to further their post-secondary education are failing to obtain a ... this year. And according to an analysis by The ... veteran students’ uninformed choice of college majors, which leads to ... the study: Some 51.7 percent of post-9/11 veterans using ...
(Date:7/28/2014)... Calif. , July 28, 2014  InterMune, Inc. ... will release its second quarter 2014 financial results at ... 6, 2014. A live conference call and webcast will be ... same day. Interested investors and others may ... or +1 212-231-2900 (international), conference ID#21728775. A replay of the ...
(Date:7/28/2014)... Research and Markets has announced the addition of ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... to determine the size of a particle in a material ... the size of particles as it can affect the functionality ... determine the behavior and nature of a material, and for ...
Breaking Biology Technology:Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4InterMune to Release Second Quarter Financial Results on August 6 2Global Particle Size Analysis Market 2014-2018 2
... from McGill,s Physics Department and Mike Lilly from Sandia ... electronic circuits. It is formed by two wires separated ... This discovery, published in the journal Nature Nanotechnology ... and power of the ever smaller integrated circuits of ...
... LONDON, December 7, 2011 Silence Therapeutics plc ... ( RNAi ) therapeutics company, announces a positive outcome from the ... (EPO) over opposition to Silence,s granted European Patent EP 1 536 ... The granted patent refers to the gene target PKN3, protein ...
... 2011  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... , 2.875% Convertible Senior Notes due February 15, 2015 ... $1,000 principal amount or approximately $6.44 per share, effective December ... May 1, 2015 (May 2015 Notes) is 135.9849 shares of ...
Cached Biology Technology:Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 2Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 3Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 4PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes 2
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
... Attoglow Western Blot Analysis Kit is ... kit developed by Biochain. It detects ... g) or yoctomole (10 -24 ... three parts: Millennium Enhancer, protein interaction ...
... BioNumerics is the universal bioinformatics software that ... data. The unique modular design of BioNumerics ... virtually any type of data employed for ... microarrays, DNA fingerprints, 2-D protein gels, HPLC, ...
... the early 80s Biosearch Technologies has ... oligonucleotide tools to accelerate the discovery ... you need dual-labeled FRET probes and ... oligos for microarray applications, Biosearch can ...
Biology Products: